Stem Cell Therapy Market - Global Forecasts to 2026

Table of Content

1 INTRODUCTION 25
1.1 OBJECTIVES OF THE STUDY 25
1.2 MARKET SCOPE 26
1.2.1 MARKETS COVERED 26
1.2.2 YEARS CONSIDERED FOR THE STUDY 26
1.3 CURRENCY 27
1.4 LIMITATIONS 27
1.5 STAKEHOLDERS 27
1.6 SUMMARY OF CHANGES 28
2 RESEARCH METHODOLOGY 29
2.1 RESEARCH APPROACH 29
FIGURE 1 RESEARCH DESIGN 29
2.1.1 SECONDARY DATA 30
2.1.2 PRIMARY DATA 31
FIGURE 2 BREAKDOWN OF PRIMARIES: STEM CELL THERAPY MARKET 31
2.1.3 MARKET DATA ESTIMATION & TRIANGULATION 32
FIGURE 3 DATA TRIANGULATION METHODOLOGY 32
2.2 MARKET ESTIMATION METHODOLOGY 33
FIGURE 4 MARKET SIZE ESTIMATION APPROACH: COMPANY REVENUE ANALYSIS (BOTTOM-UP) 33
FIGURE 5 MARKET SIZE ESTIMATION APPROACH: PARENT MARKET (TOP DOWN) 33
FIGURE 6 STEM CELL THERAPY MARKET SIZE (USD MILLION): FINAL MARKET SIZE 34
2.3 GROWTH RATE ASSUMPTIONS/GROWTH FORECAST 35
FIGURE 7 GROWTH RATE ASSUMPTION BASED ON MARKET DYNAMICS 35
FIGURE 8 FINAL CAGR PROJECTIONS (2021?2026) 35
2.4 INSIGHTS FROM PRIMARIES 36
FIGURE 9 MARKET VALIDATION FROM PRIMARY EXPERTS 36
2.5 RESEARCH ASSUMPTIONS 36
2.6 RISK ASSESSMENT 37
TABLE 1 RISK ASSESSMENT 37
3 EXECUTIVE SUMMARY 38
FIGURE 10 STEM CELL THERAPY MARKET SHARE, BY TYPE, 2020 38
FIGURE 11 STEM CELL THERAPY MARKET SHARE, BY CELL SOURCE, 2020 39
FIGURE 12 STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATIONS, 2021 VS. 2026 (USD MILLION) 39
FIGURE 13 GEOGRAPHICAL SNAPSHOT OF THE STEM CELL THERAPY MARKET 40
4 PREMIUM INSIGHTS 41
4.1 STEM CELL THERAPY MARKET OVERVIEW 41
FIGURE 14 INCREASING INVESTMENTS & FUNDING FOR STEM CELL RESEARCH IS A KEY FACTOR DRIVING MARKET GROWTH 41
4.2 NORTH AMERICA: STEM CELL THERAPY MARKET 42
FIGURE 15 ALLOGENEIC STEM CELL THERAPY TO COMMAND THE LARGEST SHARE OF THE NORTH AMERICAN STEM CELL THERAPY MARKET 42
4.3 STEM CELL THERAPY MARKET, BY CELL SOURCE 42
FIGURE 16 BONE MARROW-DERIVED MSCS TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD 42
4.4 STEM CELL THERAPY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 43
FIGURE 17 DEVELOPING MARKETS TO REGISTER HIGHER GROWTH RATES DURING THE FORECAST PERIOD 43
5 MARKET OVERVIEW 44
5.1 INTRODUCTION 44
5.2 MARKET DYNAMICS 44
FIGURE 18 STEM CELL THERAPY MARKET: DRIVERS, OPPORTUNITIES, RESTRAINTS, CHALLENGES 44
5.2.1 DRIVERS 45
5.2.1.1 Availability of funding for stem cell research 45
FIGURE 19 STEM CELL RESEARCH FUNDING IN THE LAST 10 YEARS 45
TABLE 2 NIH FUNDING FOR CELL-BASED RESEARCH, 2016–2021 (USD MILLION) 45
5.2.1.2 Increasing GMP-certification approvals for cell therapy production facilities 46
TABLE 3 RECENT DEVELOPMENTS 46
5.2.1.3 Increasing clinical trials for stem cell based-therapies 46
FIGURE 20 NUMBER OF CLINICAL TRIALS (2015-2020) 47
FIGURE 21 CLINICAL TRIALS, BY PHASE 47
5.2.2 RESTRAINTS 48
5.2.2.1 Ethical concerns related to embryonic stem cells 48
5.2.2.2 High cost of cell-based research 48
5.2.3 OPPORTUNITIES 48
5.2.3.1 The emergence of iPSCs as an alternative to ESCs 48
5.2.3.2 Growing demand for cell & gene therapies 49
5.2.4 CHALLENGES 49
5.2.4.1 Technical limitations 49
5.3 COVID-19 IMPACT ANALYSIS 49
FIGURE 22 NUMBER OF CLINICAL TRIALS FOR COVID-19 50
FIGURE 23 CLINICAL TRIALS FOR COVID-19, BY COUNTRY 50
5.4 TECHNOLOGY ANALYSIS 51
TABLE 4 STEM CELL THERAPIES AND GENE THERAPIES 51
5.5 VALUE CHAIN ANALYSIS 51
FIGURE 24 VALUE CHAIN ANALYSIS OF THE STEM CELL THERAPY MARKET 52
5.6 ECOSYSTEM MARKET MAP 52
FIGURE 25 ECOSYSTEM OF THE STEM CELL THERAPY MARKET 52
5.7 SUPPLY CHAIN 53
FIGURE 26 SUPPLY CHAIN OF STEM CELL THERAPY MARKET 53
5.8 PORTERS FIVE FORCES ANALYSIS 55
5.8.1 THREAT OF NEW ENTRANTS 55
5.8.2 THREAT OF SUBSTITUTES 55
5.8.3 BARGAINING POWER OF SUPPLIERS 56
5.8.4 BARGAINING POWER OF BUYERS 56
5.8.5 INTENSITY OF COMPETITION RIVALRY 56
5.9 REGULATORY LANDSCAPE 57
5.9.1 NORTH AMERICA 57
TABLE 5 NORTH AMERICA: REGULATORY LANDSCAPE FOR STEM CELL THERAPIES 57
5.9.2 EUROPE 59
TABLE 6 EUROPE: REGULATORY LANDSCAPE FOR STEM CELL THERAPIES 59
5.9.3 ASIA PACIFIC 60
TABLE 7 ASIA PACIFIC: REGULATORY LANDSCAPE FOR STEM CELL THERAPIES 60
5.9.4 ROW 62
TABLE 8 ROW: REGULATORY LANDSCAPE FOR STEM CELL THERAPIES 62
5.10 PRICING ANALYSIS 63
TABLE 9 PRICING ANALYSIS OF CELL THERAPY PRODUCTS 63
5.11 PATENT ANALYSIS 64
FIGURE 27 PATENT ANALYSIS OF STEM CELL THERAPY IN THE LAST 10 YEARS (2011-2020) 64
6 STEM CELL THERAPY MARKET, BY TYPE 65
6.1 INTRODUCTION 66
TABLE 10 STEM CELL THERAPY MARKET, BY TYPE, 2019–2026 (USD MILLION) 66
6.2 ALLOGENEIC STEM CELL THERAPY 66
6.2.1 EASE IN PRODUCTION PROCESSES TO DRIVE MARKET GROWTH 66
TABLE 11 ALLOGENEIC STEM CELL THERAPY MARKET, BY REGION, 2019–2026 (USD MILLION) 66
TABLE 12 NORTH AMERICA: ALLOGENEIC STEM CELL THERAPY MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 67
TABLE 13 EUROPE: ALLOGENEIC STEM CELL THERAPY MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 67
TABLE 14 APAC: ALLOGENEIC STEM CELL THERAPY MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 67
6.3 AUTOLOGOUS STEM CELL THERAPY 68
6.3.1 LOW RISK OF POST-TREATMENT COMPLICATIONS TO DRIVE THE MARKET GROWTH 68
TABLE 15 AUTOLOGOUS STEM CELL THERAPY MARKET, BY REGION, 2019–2026 (USD MILLION) 68
TABLE 16 NORTH AMERICA: AUTOLOGOUS STEM CELL THERAPY MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 68
TABLE 17 EUROPE: AUTOLOGOUS STEM CELL THERAPY MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 69
TABLE 18 APAC: AUTOLOGOUS STEM CELL THERAPY MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 69
7 STEM CELL THERAPY MARKET, BY CELL SOURCE 70
7.1 INTRODUCTION 71
TABLE 19 STEM CELL THERAPY MARKET, BY CELL SOURCE, 2019–2026 (USD MILLION) 71
7.2 ADIPOSE TISSUE-DERIVED MSCS 71
7.2.1 ADVANTAGES OF BEING EASY TO ISOLATE AND HARVEST DRIVES THE MARKET GROWTH OF THIS SEGMENT 71
TABLE 20 STEM CELL THERAPY MARKET FOR ADIPOSE TISSUE-DERIVED MSCS, BY REGION, 2019–2026 (USD MILLION) 72
TABLE 21 NORTH AMERICA: STEM CELL THERAPY MARKET FOR ADIPOSE TISSUE-DERIVED MSCS, BY COUNTRY, 2019–2026 (USD MILLION) 72
TABLE 22 EUROPE: STEM CELL THERAPY MARKET FOR ADIPOSE-TISSUE DERIVED MSCS, BY COUNTRY, 2019–2026 (USD MILLION) 72
TABLE 23 APAC: STEM CELL THERAPY MARKET FOR ADIPOSE-TISSUE DERIVED MSCS, BY COUNTRY, 2019–2026 (USD MILLION) 73
7.3 BONE MARROW-DERIVED MSCS 73
7.3.1 INCREASING CASES OF METABOLIC DISORDERS TO SUPPORT MARKET GROWTH OF THIS SEGMENT 73
TABLE 24 STEM CELL THERAPY MARKET FOR BONE MARROW-DERIVED MSCS, BY REGION, 2019–2026 (USD MILLION) 74
TABLE 25 NORTH AMERICA: STEM CELL THERAPY MARKET FOR BONE MARROW-DERIVED MSCS, BY COUNTRY, 2019–2026 (USD MILLION) 74
TABLE 26 EUROPE: STEM CELL THERAPY MARKET FOR BONE MARROW-DERIVED MSCS, BY COUNTRY, 2019–2026 (USD MILLION) 74
TABLE 27 APAC: STEM CELL THERAPY MARKET FOR BONE MARROW-DERIVED MSCS, BY COUNTRY, 2019–2026 (USD MILLION) 75
7.4 PLACENTA/UMBILICAL CORD-DERIVED MSCS 75
7.4.1 LOW CHANCES OF REJECTION FROM THE IMMUNE SYSTEM IS LIKELY TO SUPPORT MARKET GROWTH OF THIS SEGMENT 75
TABLE 28 STEM CELL THERAPY MARKET FOR PLACENTA/UMBILICAL CORD-DERIVED MSCS, BY REGION, 2019–2026 (USD MILLION) 76
TABLE 29 NORTH AMERICA: STEM CELL THERAPY MARKET FOR PLACENTA/UMBILICAL CORD-DERIVED MSCS, BY COUNTRY, 2019–2026 (USD MILLION) 76
TABLE 30 EUROPE: STEM CELL THERAPY MARKET FOR PLACENTA/UMBILICAL CORD-DERIVED MSCS, BY COUNTRY, 2019–2026 (USD MILLION) 76
TABLE 31 APAC: STEM CELL THERAPY MARKET FOR PLACENTA/UMBILICAL CORD-DERIVED MSCS, BY COUNTRY, 2019–2026 (USD MILLION) 77
7.5 OTHER CELL SOURCES 77
TABLE 32 STEM CELL THERAPY MARKET FOR OTHER CELL SOURCES, BY REGION, 2019–2026 (USD MILLION) 77
TABLE 33 NORTH AMERICA: STEM CELL THERAPY MARKET FOR OTHER CELL SOURCES, BY COUNTRY, 2019–2026 (USD MILLION) 78
8 STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION 79
8.1 INTRODUCTION 80
TABLE 34 STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2019–2026 (USD MILLION) 80
8.2 MUSCULOSKELETAL DISORDERS 80
8.2.1 INCREASING CASES OF OSTEOARTHRITIS TO DRIVE THE MARKET GROWTH OF THIS SEGMENT 80
TABLE 35 MUSCULOSKELETAL DISORDERS MARKET, BY REGION, 2019–2026 (USD MILLION) 81
TABLE 36 NORTH AMERICA: MUSCULOSKELETAL DISORDERS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 81
TABLE 37 EUROPE: MUSCULOSKELETAL DISORDERS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 81
TABLE 38 APAC: MUSCULOSKELETAL DISORDERS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 82
8.3 WOUNDS & INJURIES 82
8.3.1 INCREASING BENEFITS OF ALLOGENEIC-BASED THERAPIES TO SUPPORT THE MARKET GROWTH 82
TABLE 39 WOUNDS & INJURIES MARKET, BY REGION, 2019–2026 (USD MILLION) 82
TABLE 40 NORTH AMERICA: WOUNDS & INJURIES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 83
TABLE 41 EUROPE: WOUNDS & INJURIES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 83
TABLE 42 APAC: WOUNDS & INJURIES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 83
8.4 INFLAMMATORY & AUTOIMMUNE DISEASES 84
8.4.1 INCREASING CLINICAL TRIALS FOR THIS SEGMENT IS LIKELY TO SUPPORT MARKET GROWTH 84
TABLE 43 INFLAMMATORY & AUTOIMMUNE DISEASES MARKET, BY REGION, 2019–2026, (USD MILLION) 84
TABLE 44 NORTH AMERICA: INFLAMMATORY & AUTOIMMUNE DISEASES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 84
TABLE 45 EUROPE: INFLAMMATORY & AUTOIMMUNE DISEASES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 85
TABLE 46 APAC: INFLAMMATORY & INFLAMMATORY DISEASES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 85
8.5 SURGERIES 85
8.5.1 INCREASING CLINICAL RESEARCH FOR SURGICAL APPLICATIONS TO SUPPORT MARKET GROWTH 85
TABLE 47 SURGERIES MARKET, BY REGION, 2019–2026 (USD MILLION) 86
TABLE 48 NORTH AMERICA: SURGERIES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 86
TABLE 49 EUROPE: SURGERIES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 86
TABLE 50 APAC: SURGERIES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 87
8.6 CARDIOVASCULAR DISEASES 87
8.6.1 INCREASING PUBLIC & PRIVATE FUNDING FOR CVD RESEARCH IS LIKELY TO SUPPORT MARKET GROWTH 87
TABLE 51 CARDIOVASCULAR DISEASES MARKET, BY REGION, 2019–2026 (USD MILLION) 87
TABLE 52 NORTH AMERICA: CARDIOVASCULAR DISEASES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 88
TABLE 53 EUROPE: CARDIOVASCULAR DISEASES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 88
TABLE 54 APAC: CARDIOVASCULAR DISEASES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 88
8.7 NEUROLOGICAL DISORDERS 89
8.7.1 RISING PREVALENCE OF NEUROGENERATIVE DISORDERS SUPPORTS MARKET GROWTH OF THIS SEGMENT 89
TABLE 55 NEUROLOGICAL DISORDERS MARKET, BY REGION, 2019–2026 (USD MILLION) 89
TABLE 56 NORTH AMERICA: NEUROLOGICAL DISORDERS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 89
TABLE 57 EUROPE: NEUROLOGICAL DISORDERS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 90
TABLE 58 APAC: NEUROLOGICAL DISORDERS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 90
8.8 OTHER THERAPEUTIC APPLICATIONS 90
TABLE 59 OTHER THERAPEUTIC APPLICATIONS MARKET, BY REGION, 2019–2026 (USD MILLION) 90
TABLE 60 NORTH AMERICA: OTHER THERAPEUTIC APPLICATIONS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 91
9 STEM CELL THERAPY MARKET, BY REGION 92
9.1 INTRODUCTION 93
FIGURE 28 STEM CELL THERAPY MARKET SNAPSHOT 93
TABLE 61 STEM CELL THERAPY MARKET, BY REGION, 2019–2026 (USD MILLION) 93
9.2 NORTH AMERICA 94
FIGURE 29 NORTH AMERICA: STEM CELL THERAPY MARKET SNAPSHOT 94
TABLE 62 NORTH AMERICA: STEM CELL THERAPY MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 95
TABLE 63 NORTH AMERICA: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2019–2026 (USD MILLION) 95
TABLE 64 NORTH AMERICA: STEM CELL THERAPY MARKET, BY TYPE, 2019–2026 (USD MILLION) 95
TABLE 65 NORTH AMERICA: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2019–2026 (USD MILLION) 96
9.2.1 US 96
9.2.1.1 Increasing investments and funding for stem cell research drive the market growth in the UK 96
FIGURE 30 NIH FUNDING IN THE LAST 10 YEARS (2011?2021) 96
TABLE 66 US: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2019–2026 (USD MILLION) 97
TABLE 67 US: STEM CELL THERAPY MARKET, BY TYPE, 2019–2026 (USD MILLION) 97
TABLE 68 US: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2019–2026 (USD MILLION) 97
9.2.2 CANADA 98
9.2.2.1 Rising approvals of stem cell therapies in Canada are likely to boost the market 98
TABLE 69 CANADA: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2019–2026 (USD MILLION) 98
TABLE 70 CANADA: STEM CELL THERAPY MARKET, BY TYPE, 2019–2026 (USD MILLION) 98
TABLE 71 CANADA: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2019–2026 (USD MILLION) 99
9.3 EUROPE 99
TABLE 72 EUROPE: STEM CELL THERAPY MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 99
TABLE 73 EUROPE: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2019–2026 (USD MILLION) 100
TABLE 74 EUROPE: STEM CELL THERAPY MARKET, BY TYPE, 2019–2026 (USD MILLION) 100
TABLE 75 EUROPE: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2019–2026 (USD MILLION) 100
9.3.1 GERMANY 101
9.3.1.1 Strong R&D base and focus on minimally invasive surgeries to drive market growth in Germany 101
TABLE 76 GERMANY: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2019–2026 (USD MILLION) 101
TABLE 77 GERMANY: STEM CELL THERAPY MARKET, BY TYPE, 2019–2026 (USD MILLION) 101
TABLE 78 GERMANY: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2019–2026 (USD MILLION) 102
9.3.2 UK 102
9.3.2.1 The rising adoption of cell-based therapies in the UK drives the market growth 102
TABLE 79 UK: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2019–2026 (USD MILLION) 102
TABLE 80 UK: STEM CELL THERAPY MARKET, BY TYPE, 2019–2026 (USD MILLION) 103
TABLE 81 UK: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2019–2026 (USD MILLION) 103
9.3.3 FRANCE 103
9.3.3.1 Rising healthcare expenditure is likely to drive market growth in France for stem cell therapy 103
TABLE 82 FRANCE: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2019–2026 (USD MILLION) 104
TABLE 83 FRANCE: STEM CELL THERAPY MARKET, BY TYPE, 2019–2026 (USD MILLION) 104
TABLE 84 FRANCE: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2019–2026 (USD MILLION) 104
9.3.4 REST OF EUROPE 105
TABLE 85 ROE: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2019–2026 (USD MILLION) 105
TABLE 86 ROE: STEM CELL THERAPY MARKET, BY TYPE, 2019–2026 (USD MILLION) 105
TABLE 87 ROE: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2019–2026 (USD MILLION) 106
9.4 ASIA PACIFIC 107
FIGURE 31 ASIA PACIFIC: STEM CELL THERAPY MARKET SNAPSHOT 107
TABLE 88 APAC: STEM CELL THERAPY MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 108
TABLE 89 APAC: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2019–2026 (USD MILLION) 108
TABLE 90 APAC: STEM CELL THERAPY MARKET, BY TYPE, 2019–2026 (USD MILLION) 108
TABLE 91 APAC: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2019–2026 (USD MILLION) 109
9.4.1 JAPAN 109
9.4.1.1 Growing geriatric population and faster regulatory approval process is expected to augment market growth in Japan 109
TABLE 92 JAPAN: STEM CELL THERAPY MARKET, BY CELL SOURCE 2019–2026 (USD MILLION) 109
TABLE 93 JAPAN: STEM CELL THERAPY MARKET, BY TYPE, 2019–2026 (USD MILLION) 110
TABLE 94 JAPAN: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2019–2026 (USD MILLION) 110
9.4.2 SOUTH KOREA 110
9.4.2.1 The presence of major players supports market growth in South Korea 110
TABLE 95 SOUTH KOREA: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2019–2026 (USD MILLION) 111
TABLE 96 SOUTH KOREA: STEM CELL THERAPY MARKET, BY TYPE, 2019–2026 (USD MILLION) 111
TABLE 97 SOUTH KOREA: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2019–2026 (USD MILLION) 111
9.4.3 INDIA 112
9.4.3.1 Rising number of neurodegenerative disorders to drive market growth in India 112
TABLE 98 INDIA: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2019–2026 (USD MILLION) 112
TABLE 99 INDIA: STEM CELL THERAPY MARKET, BY TYPE, 2019–2026 (USD MILLION) 112
TABLE 100 INDIA: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2019–2026 (USD MILLION) 113
9.4.4 REST OF ASIA PACIFIC 113
TABLE 101 ROAPAC: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2019–2026 (USD MILLION) 113
TABLE 102 ROAPAC: STEM CELL THERAPY MARKET, BY TYPE, 2019–2026 (USD MILLION) 114
TABLE 103 ROAPAC: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2019–2026 (USD MILLION) 114
9.5 REST OF THE WORLD 114
TABLE 104 ROW: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2019–2026 (USD MILLION) 115
TABLE 105 ROW: STEM CELL THERAPY MARKET, BY TYPE, 2019–2026 (USD MILLION) 115
TABLE 106 ROW: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2019–2026 (USD MILLION) 115
10 COMPETITIVE LANDSCAPE 116
10.1 OVERVIEW 116
10.2 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS 116
FIGURE 32 TOP MARKET PLAYERS DOMINATE THE STEM CELL THERAPY MARKET 117
10.3 MARKET SHARE ANALYSIS 117
FIGURE 33 STEM CELL THERAPY MARKET RANK, BY KEY PLAYER (2020) 117
TABLE 107 STEM CELL THERAPY MARKET: DEGREE OF COMPETITION 118
10.4 COMPETITIVE LEADERSHIP MAPPING 118
10.4.1 STARS 119
10.4.2 EMERGING LEADERS 119
10.4.3 PERVASIVE PLAYERS 119
10.4.4 PARTICIPANTS 119
FIGURE 34 STEM CELL THERAPY MARKET: COMPANY EVALUATION QUADRANT (2020)- APPROVED PRODUCTS 120
10.5 STEM CELL THERAPY MARKET: SME EVALUATION MATRIX, 2020 (UNDER PIPELINE) 121
10.5.1 PROGRESSIVE COMPANIES 121
10.5.2 STARTING BLOCKS 121
10.5.3 RESPONSIVE COMPANIES 121
10.5.4 DYNAMIC COMPANIES 121
FIGURE 35 STEM CELL THERAPY MARKET: SME EVALUATION MATRIX, 2020 (UNDER PIPELINE) 122
10.6 COMPANY PRODUCT FOOTPRINT 123
FIGURE 36 PRODUCT PORTFOLIO ANALYSIS BY APPLICATION: STEM CELL THERAPY MARKET 123
10.7 COMPANY GEOGRAPHIC FOOTPRINT OF MAJOR PLAYERS IN THE STEM CELL THERAPY MARKET 124
FIGURE 37 GEOGRAPHIC REVENUE MIX: STEM CELL THERAPY MARKET (2020) 124
10.8 COMPETITIVE SCENARIO 125
10.8.1 PRODUCT LAUNCHES 125
10.8.2 DEALS 125
TABLE 109 STEM CELL THERAPY MARKET: DEALS, MARCH 2019–JANUARY 2021 125
10.8.3 OTHER DEVELOPMENTS 125
TABLE 110 STEM CELL THERAPY MARKET: OTHER DEVELOPMENTS (MAY 2019–NOVEMBER 2020) 126
11 COMPANY PROFILES 127
11.1 MAJOR PLAYERS 127
(Business Overview, Products Offered, Recent Developments, MnM View)*
11.1.1 SMITH & NEPHEW 127
TABLE 111 SMITH & NEPHEW: BUSINESS OVERVIEW 127
FIGURE 38 SMITH & NEPHEW: COMPANY SNAPSHOT (2020) 128
TABLE 112 SMITH & NEPHEW : PRODUCTS OFFERED 128
11.1.2 MEDIPOST 130
TABLE 113 MEDIPOST : BUSINESS OVERVIEW 130
FIGURE 39 MEDIPOST: COMPANY SNAPSHOT (2019) 130
TABLE 114 MEDIPOST : PRODUCTS OFFERED 130
11.1.3 ANTEROGEN 133
TABLE 115 ANTEROGEN: BUSINESS OVERVIEW 133
TABLE 116 ANTEROGEN: PRODUCTS OFFERED 133
11.1.4 CORESTEM 134
TABLE 117 CORESTEM : BUSINESS OVERVIEW 134
TABLE 118 CORESTEM: PRODUCTS OFFERED 134
11.1.5 PHARMICELL 135
TABLE 119 PHARMICELL : BUSINESS OVERVIEW 135
TABLE 120 PHARMICELL: PRODUCTS OFFERED 135
11.1.6 NUVASIVE 136
TABLE 121 NUVASIVE: BUSINESS OVERVIEW 136
FIGURE 40 NUVASIVE: COMPANY SNAPSHOT (2020) 136
TABLE 122 NUVASIVE: PRODUCTS OFFERED 137
11.1.7 RTI SURGICAL 138
TABLE 123 RTI SURGICAL : BUSINESS OVERVIEW 138
TABLE 124 RTI SURGICAL: PRODUCTS OFFERED 138
11.1.8 ALLOSOURCE 139
TABLE 125 ALLOSOURCE: BUSINESS OVERVIEW 139
TABLE 126 ALLOSOURCE: PRODUCTS OFFERED 139
11.1.9 JCR PHARMACEUTICALS 140
TABLE 127 JCR PHARMACEUTICALS: BUSINESS OVERVIEW 140
FIGURE 41 JCR PHARMACEUTICALS: COMPANY SNAPSHOT (2019) 140
TABLE 128 JCR PHARMACEUTICALS: PRODUCTS OFFERED 141
11.1.10 TAKEDA PHARMACEUTICAL COMPANY 142
TABLE 129 TAKEDA PHARMACEUTICAL COMPANY: BUSINESS OVERVIEW 142
FIGURE 42 TAKEDA PHARMACEUTICAL COMPANY: COMPANY SNAPSHOT (2019) 142
TABLE 130 TAKEDA PHARMACEUTICAL COMPANY: PRODUCTS OFFERED 143
11.1.11 HOLOSTEM TERAPIE AVANZATE 144
TABLE 131 HOLOSTEM TERAPIE AVANZATE : BUSINESS OVERVIEW 144
TABLE 132 HOLOSTEM TERAPIE AVANZATE : PRODUCTS OFFERED 144
11.1.12 ORTHOFIX 145
TABLE 133 ORTHOFIX : BUSINESS OVERVIEW 145
FIGURE 43 ORTHOFIX: COMPANY SNAPSHOT (2019) 145
TABLE 134 ORTHOFIX: PRODUCTS OFFERED 146
11.1.13 STEMPEUTICS RESEARCH 147
11.1.14 REGROW BIOSCIENCES 147
11.2 OTHER PLAYERS (UNDER PIPELINE) 148
11.2.1 ATHERSYS 148
TABLE 135 ATHERSYS: BUSINESS OVERVIEW 148
FIGURE 44 ATHERSYS: COMPANY SNAPSHOT (2019) 148
TABLE 136 ATHERSYS: PRODUCTS OFFERED 148
11.2.2 MESOBLAST 149
TABLE 137 MESOBLAST: BUSINESS OVERVIEW 149
FIGURE 45 MESOBLAST: COMPANY SNAPSHOT (2020) 149
TABLE 138 MESOBLAST: PRODUCTS OFFERED 149
11.2.3 BIORESTORATIVE THERAPIES 150
TABLE 139 BIORESTORATIVE THERAPIES : BUSINESS OVERVIEW 150
TABLE 140 BIORESTORATIVE THERAPIES: PRODUCTS OFFERED 150
11.2.4 PLURISTEM THERAPUTICS 151
TABLE 141 PLURISTEM THERAPIES: BUSINESS OVERVIEW 151
TABLE 142 PLURISTEM THERAPIES: PRODUCTS OFFERED 151
11.2.5 BRAINSTORM CELL THERAPEUTICS 152
11.2.6 GAMIDA CELL 152
11.2.7 VIACYTE 152
11.2.8 KANGSTEM BIOTECH 153
11.2.9 HOPE BIOSCIENCES 153
11.2.10 CELLULAR BIOMEDICINE GROUP 153
11.2.11 PERSONALIZED STEM CELLS 154
*Business Overview, Products Offered, Recent Developments, MnM View might not be captured in case of unlisted companies.
12 APPENDIX 155
12.1 DISCUSSION GUIDE 155
12.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 157
12.3 AVAILABLE CUSTOMIZATIONS 159
12.4 RELATED REPORTS 159
12.5 AUTHOR DETAILS 160